๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 38 Shanghai 34 Beijing 24 Chengdu 13 Wuhan 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University8 The First Affiliated Hospital of Guangzhou Medical University6 AstraZeneca4 Guangdong Provincial People's Hospital3 ChromX Health2
Site location
Guangzhou38 Shanghai34 Beijing24 Chengdu13 Wuhan11
All 49 locations
Target enrolment
to

Trials with a site in Guangzhou

38 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
TROP2 NMR Concordance Study
NCT07624318Lung Cancer
AstraZeneca
Observational
3,400
Beijing, Guangzhou, Shanghai
2026-08-13
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
NCT07645222Lung Cancer
Hansoh BioMedical R&D Company
Phase 1
396
Guangzhou
2026-06-15
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer
NCT07412327Early-Stage Lung Cancer, Lung Cancer
Guangzhou Concord Cancer Center
Not applicable
65
Guangzhou
2026-02-24
Not yet open
Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
NCT07352176Pulmonary Lesion, Lung Cancer
Guangzhou Medical University
Not applicable
40
Guangzhou
2026-02-01
Recruiting
Large Language Models Assist in Tumor MDT
NCT07504367Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
60
Guangzhou
2026-01-01
Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
NCT07241767Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-11-12
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
NCT06607770Lung Cancer
Zhou Chengzhi
Phase 1/2
20
Guangzhou
2024-09-01
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
NCT06988579Lung Cancer, Artificial Intelligence (AI), Randomized Controlled Trial
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
7,294
Guangzhou
2024-07-01
Recruiting
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
NCT06528418Lung Cancer, Lung Infection, COPD, Bronchitis
ChromX Health
Observational
10,000
Guangzhou
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Recruiting
GPC3/Mesothelin-CAR-ฮณฮดT Cells Against Cancers
NCT06196294Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-10
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT06483347Lung Cancer, Inoperable Disease
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guangzhou
2024-04-04
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
NCT06478108Lung Cancer, Liver Cancer, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3
60
Guangzhou
2024-04-01
Recruiting
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
NCT06383728Lung Cancer, Carcinoma, Squamous Cell
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
51
Guangzhou
2024-04-01
Recruiting
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
NCT06244264Spinal Metastases, Blood Transfusion Complication, Lung Cancer, Surgery
Guangdong Provincial People's Hospital
Not applicable
118
Guangzhou
2024-03-15
Recruiting
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
NCT06607796Lung Cancer
Zhou Chengzhi
Phase 3
180
Guangzhou
2024-03-01
Recruiting
Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
NCT06215326Lung Cancer
Guangdong Provincial People's Hospital
Not applicable
100
Guangzhou
2024-01-23
Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
NCT06843707Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2024-01-01
Recruiting
Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
NCT06286150Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
20
Guangzhou
2023-09-15
Active, closed
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
NCT05690945Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3
606
Guangzhou
2023-02-15
Active, closed
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
NCT04841811Lung Cancer
Guangdong Association of Clinical Trials
Phase 3
192
Guangzhou
2022-06-20
Recruiting
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
NCT06019455Lung Cancer, Esophageal Cancer
Sun Yat-sen University
Observational
500
Guangzhou
2022-06-01
Recruiting
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
100
Guangzhou
2021-11-01
Recruiting
MRD Monitoring in Lung Cancer After Resection
NCT04976296Lung Cancer
Guangdong Provincial People's Hospital
Observational
300
Guangzhou
2021-09-01
Recruiting
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
NCT04952272Lung Cancer, Hepatocellular Carcinoma, Solid Tumor
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
50
Guangzhou
2021-03-01
Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
NCT04842812Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
40
Guangzhou
2021-01-01
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Recruiting
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
NCT04286841Immunotherapy, Lung Cancer
Guangdong Association of Clinical Trials
Observational
100
Guangzhou
2019-05-01
Recruiting
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
NCT03192501Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer
Second Affiliated Hospital of Guangzhou Medical University
Observational
250
Guangzhou
2017-07-01
Recruiting
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFฮฒ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
NCT03198052Lung Cancer, Cancer, Immunotherapy, CAR-T Cell
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
Non-risk Based Lang Cancer Screening With a One-off LDCT
NCT04938804Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
11,000
Guangzhou
2015-12-12
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

33 of the 38 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 38 studies
PhaseStudiesRecruitingShare
Observational121231.6%
Not applicable9823.7%
Phase 15513.2%
Phase 25413.2%
Phase 34110.5%
Phase 1/2225.3%
Phase 2/3112.6%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Guangzhou Medical University88
The First Affiliated Hospital of Guangzhou Medical University66
AstraZeneca43
Guangdong Provincial People's Hospital33
ChromX Health22
Guangdong Association of Clinical Trials21
Zhou Chengzhi22
Guangzhou Concord Cancer Center11
Guangzhou Medical University10
Hansoh BioMedical R&D Company11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.